See how funds raised at B.C.'s largest cycling fundraiser ensure BC Cancer researchers and clinicians have the support needed to re-invent the standard of cancer care.





The Ride has supported more than 47 projects, investigating more than 50 different cancer types




Ride dollars support BC Cancer’s Ovarian Cancer Research Program (OVCARE)—a globally recognized team with two world-first prevention strategies: the removal of fallopian tubes during routine hysterectomy, and hereditary genetic testing at the time of diagnosis, actions deployed across B.C. 
The Personalized Onco-Genomics (POG) Program allows BC Cancer’s world-leading scientists and doctors to map the genomic structure of a patient’s cancer to help determine potential drug targets and treatment based on a biological rationale. Funds from The Ride enable us to continue enrolling patients into this ground-breaking clinical study. 
Tests in development will help prevent nearly half of all lymphoma patients from facing a relapse. The Ride has helped researchers at BC Cancer’s Centre for Lymphoid Cancer secure prestigious research grants that will change the outcome for many patients with lymphoma and other blood cancers in B.C. and beyond.
Advanced Immunotherapy treatment development

Funds support incredible progress for BC Cancer’s immunotherapy research program, with the team gearing up to bring these home-grown, cutting-edge treatments to patients. The Ride will help make T cell therapy a reality for cancer patients facing leukemia, lymphoma and gynecologic cancers in B.C. 


Ride funds are fueling a new, world-leading Molecular Imaging and Therapeutics program at BC Cancer spanning research and development of cutting-edge radiopharmaceuticals through to clinical trials. 

Patients in northern B.C. have greater support to overcome health and financial challenges thanks to Ride funds, specifically from the devoted Wheelin’ Warriors of the North team. 

Funds also support a precision radiation therapy hub at BC Cancer – Prince George. “By establishing a research program and acquiring vital new equipment, we can have a direct impact for patients in the North and across B.C.,” says Dr. Robert Olson, radiation oncologist. 

Funds raised through The Ride supported the recent purchase of two PET/CT scanners—one in Victoria and one in Kelowna. These machines will bring world-class diagnostics closer to home for thousands of patients in need and will help reduce wait times across the province. 


A multi-gene analysis panel is available to oncologists across B.C. as a provincial diagnostic tool, meaning a more personalized approach to treatment for thousands of eligible cancer patients. This is the first gene panel to be available province-wide and as part of standard cancer care in Canada for acquired cancers. Ride support took this test from idea, to the clinic and has helped in treatment planning for more than 3,500 patients to date.
Ride dollars have helped place BC Cancer’s breast team on the world stage. Thanks to funding and research, B.C. has the best breast cancer outcomes in the world. 

The team, led by Dr. Samuel Aparicio, identified 10 unique sub-types of breast cancer, decoding the genomic structure of the most deadly of these and proving that cancer has the ability to change over time and in response to treatments. 

Today, patients can enter B-PRECISE, the world’s largest breast cancer study where tumour tissue is collected the time of diagnosis to conduct DNA sequencing.

Through the Personalized Onco-Genomics Program, 61 brain cancer patients have been enrolled, 41 are pediatric; where the genomic profile of their cancer is analyzed to provide highly personalized treatment planning.

Brain cancer care in B.C. has been transformed, enabling patients to be seen by neuro-oncology specialists quickly and effectively, in one visit and at one site.

At BC Cancer – Victoria a stereotactic radiotherapy program for brain cancer started treating patients with multiple metastases in early 2016. These individuals can benefit from modern treatment technology, which allows highly accurate (1-2 mm precision), efficient and effective radiotherapy treatment.

Ride support is helping to dramatically improve the lives of young cancer patients. By studying a rare childhood cancer, Dr. Poul Sorensen discovered a gene-fusion in the ‘90s, which has led to a new drug, one of the first to be approved for use based on a genetic driver vs. tumour type. There are at least 22 cancer types known to harbor this gene-fusion meaning many patients around the world have a new treatment option on the way.